Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452775 · ClinicalTrials.gov registry record · Phase 1
Autologous OC-L Vaccine and Ovarian Cancer
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02452775: Clinical Trial Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02452775 is a Phase 1 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02452775, a Phase 1 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a randomized pilot trial to test the addition of 2 investigational agents, Montanide and poly-ICLC (a TLR3 agonist) to a backbone of autologous oxidized tumor cell lysate vaccine (OC-L) administered with GMCSF in subjects with primary epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Interventions
- OTHER Montanide
- BIOLOGICAL OC-L
- OTHER poly-ICLC (Hiltonol),
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-05-30 |
| Phase | Phase 1 |
Why NCT02452775 stopped before completion
NCT02452775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 3 interventions - of which Montanide is the first listed.
NCT02452775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02452775 about?
NCT02452775 is a clinical study titled "Autologous OC-L Vaccine and Ovarian Cancer". This is a randomized pilot trial to test the addition of 2 investigational agents, Montanide and poly-ICLC (a TLR3 agonist) to a backbone of autologous oxidized tumor cell lysate vaccine (OC-L) administered with GMCSF in subjects with primary epithelial ovarian, fallopian tube, or primary peritoneal...
What is the current status of trial NCT02452775?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2015-05. Estimated completion is 2018-05-30.
What interventions are being tested in trial NCT02452775?
The interventions under investigation include: Montanide (OTHER), OC-L (BIOLOGICAL), poly-ICLC (Hiltonol), (OTHER).
Who is sponsoring clinical trial NCT02452775?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02452775's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia